ProMetic Biosciences Inc., the therapeutic subsidiary of ProMetic Life Sciences Inc. (TSX:PLI.SV), today announced completion of the phase I clinical trial of PBI-1402, a novel therapeutic compound in development to treat patients with anemia. These results were positive in that PBI-1402, given orally to healthy volunteers at a higher dose than used in the previous part of phase I trial, continues to show a good safety profile without any significant adverse effects.
